Alkem gets two observations from USFDA for USA plant

At the end of the inspection, the company received Form 483 with two observations, Alkem Laboratories said in a regulatory filing.

Picture: Pixabay

Last Updated on June 21, 2021 by The Health Master

Alkem Laboratories on Saturday said the US health regulator has issued two observations after inspection of its St Louis-based manufacturing facility. The US Food and Drug Administration (USFDA) had conducted an inspection of the company’s manufacturing plant at St Louis, USA from June 14-18, 2021.

At the end of the inspection, the company received Form 483 with two observations, Alkem Laboratories said in a regulatory filing.

The company shall submit to USFDA within the stipulated timeline, a detailed response to close out all the observations associated with this inspection, the drug firm said.

Picture: Pixabay

An USFDA Form 483 is issued to a firm management at the conclusion of an inspection when an investigator has observed any conditions that in their judgment may constitute violations of the Food Drug and Cosmetic Act and related Acts.

It notifies the company’s management of objectionable conditions at the facility.

Alkem, which has operations spread across multiple territories abroad, produces a complete range of formulations of controlled substances at its finished dosage manufacturing facility in St Louis, Missouri.

Lupin gets USFDA nod for treatment of Kidney patient

Aleor gets USFDA nod for Testosterone Topical Solution

Avenue Therapeutics gets complete response letter from USFDA for IV Tramadol

Natco gets USFDA nod for Carfilzomib Injection

Lupin gets warning letter from USFDA for Somerset facility

Lupin gets USFDA nod for generic drug to treat HIV infection

Application Forms: All types of Cosmetics

Application Forms: All types of Drugs

Schedules: All types of Clinical Trials

Schedules: All types of Cosmetics

Schedules: All types of Medical Devices

NPPA directs Mfrs, Mkts Cos to pass on benefit of reduced…

Subscribe for daily free updates


Enter your email address:

Delivered by FeedBurner